HPLC Purity and MS Identity: What a Peptide Release Panel Actually Resolves
A peptide batch leaves purification as a solution of one intended molecule plus whatever else the process made. Two questions follow. How much of what is in the vial is the target — that is purity, and it is normally answered by chromatography. And is the main peak the molecule you meant to make — that is identity, and it is normally answered by mass spectrometry. The two checks are routinely reported together, and they fail in different places.
Why impurities exist at all
No production route gives a clean product. A review of preparative chromatography for therapeutic peptides lists the main manufacturing methods as enzymatic hydrolysis, microbial fermentation, recombinant approaches and, especially, chemical synthesis, and states that none of these produce exclusively the target product [1]. The other species are impurities that must be removed for safety and pharmaceutical quality reasons [1]. Preparative liquid chromatography is described as the purification method of choice, chosen for its flexibility in matching conditions case by case to the particular separation problem [1].
Purity control matters because small amounts of the wrong thing have consequences downstream. Work on peptide purification transfer states that even minor impurities can alter biological activity, distort analytical results and compromise downstream applications [5].
What reversed-phase HPLC resolves, and what it does not
Reversed-phase separation is the workhorse, but resolution is not uniform across impurity types. For peptides carrying basic amino acids, a dynamic electrostatic-repulsion reversed-phase approach (d-ERRP) has been reported to give what the authors describe as unprecedented resolution of related impurities, including epimeric isobaric ones — that is, impurities with the same mass as the target [3]. The authors present it as a superior analytical tool for evaluating the quality of these drugs on the market [3]. The point for a QC group is structural: if your peptide is basic, the ordinary reversed-phase method may be leaving co-eluting impurities inside the main peak, and the fix is a different selectivity, not a longer gradient.
Parameter choice drives the outcome. A systematic evaluation using a defined peptide impurity library quantified the effects of gradient steepness, flow rate, temperature and mobile-phase modifier on selectivity, resolution and transferability, and found that flow-rate optimisation and modifier choice have the greatest impact on separation quality [5]. The same work explored replacing trifluoroacetic acid with formic acid as a greener modifier, reporting selective improvements in separation performance [5]. Modifier choice is not only a separation decision — it is also the point where an analytical method becomes compatible, or incompatible, with mass spectrometric detection downstream.
Carrying an analytical method onto a preparative system
An analytical HPLC method and the preparative run it is meant to guide are not the same system. The transfer study reports that reliable translation of analytical HPLC results to preparative FPLC conditions remains challenging because of system-specific differences in column geometry, gradient formation and mobile-phase chemistry [5]. The authors developed a correction equation to compensate for system-dependent deviations, reducing transfer errors in elution percentage from approximately 17% to less than 5% [5]. With the optimised workflow, initial preparative purifications reached purities above 90% with yields exceeding 30% [5]. The review of preparative chromatography also points to continuous processing, naming Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) as a recent continuous chromatographic process [1].
Where mass gives no answer
Mass spectrometry establishes identity by measuring mass, so it is blind to impurities that weigh the same as the product. Two cases in the evidence show this clearly.
The first is aspartic acid isomerisation. Isomerisation of aspartic acid to isoaspartic acid is described as a common isobaric impurity that can be very difficult to identify without first synthesising isoAsp peptide standards for comparison by chromatography [2]. A study using a cyclic ion mobility (cIMS) mass spectrometry system — a conformation-selective method — examined a therapeutic peptide and three synthetic isomeric forms, each with a single Asp residue isomerised [2]. cIMS showed distinct conformational differences between each peptide and, with a simple workflow for comparing ion mobility data, correctly located which Asp residue had isomerised in each case [2]. The authors present the technique as a potential screening tool for peptides prone to isoAsp formation [2].
The second is cyclisation. For cyclic peptides made from isomeric linear precursors by intramolecular click chemistry, assessing purity by mass spectrometry is described as a significant challenge because the linear and cyclic peptides have identical masses [4]. One study compared energy-resolved mass spectrometry — collision-induced dissociation tandem MS in an ion trap at several excitation energies — with mid-infrared microscopy [4]. IR microscopy quantified the linear peptide using the absorbance of an alkyne band specific to that form, and was linear across the whole working interval from pure cyclic to pure linear [4]. The ER MS calibration models were linear only up to a 0.3 linear-peptide molar ratio, but gave better limit of detection, intermediate precision and root-mean-square error of calibration, making ER MS the preferred choice for detecting and quantifying the lowest relative amounts of linear peptide [4]. In both studies, multivariate calibration using the full data set outperformed single-point univariate models [4].
Peptide mapping as a combined purity-and-identity readout
For larger protein products, LC-MS peptide mapping run as a multi-attribute method (MAM) is reported to have the potential to replace multiple conventional HPLC- and capillary-electrophoresis-based purity and impurity assays for release and stability testing [6]. The prerequisite is new peak detection (NPD) — the ability to reliably flag new, absent and changed peptide species [6]. A published NPD workflow with rationally designed detection thresholds was validated according to ICH Q2 guidelines and, in case studies covering drug product stability and unknown impurities in drug substance, reliably recognised relevant peptide species below 1% relative abundance without reporting false positive peaks [6].
Anchoring the number to a standard
What to ask for
When reviewing a release package, treat purity and identity as separate claims with separate failure modes. Ask which impurities the chromatographic method is known to resolve, not just what number the main peak reports — epimeric and isobaric related substances may sit under it [3]. Ask whether the analytical method and the preparative method were linked deliberately, since system differences in column geometry, gradient formation and mobile-phase chemistry otherwise introduce transfer error [5]. Ask how isomeric species are addressed, because mass alone cannot distinguish isoAsp from Asp [2] or a cyclic peptide from its linear isomer [4].
References
- De Luca C, Lievore G, Bozza D, Buratti A, Cavazzini A, Ricci A, Macis M, Cabri W, Felletti S, Catani M. Downstream Processing of Therapeutic Peptides by Means of Preparative Liquid Chromatography — Molecules (Basel, Switzerland), 2021-08-03.
- Gibson K, Cooper-Shepherd DA, Pallister E, Inman SE, Jackson SE, Lindo V. Toward Rapid Aspartic Acid Isomer Localization in Therapeutic Peptides Using Cyclic Ion Mobility Mass Spectrometry — Journal of the American Society for Mass Spectrometry, 2022-05-24.
- Mazzoccanti G, Manetto S, Bassan M, Foschini A, Orlandin A, Ricci A, Cabri W, Ismail OH, Catani M, Cavazzini A, Gasparrini F. Boosting basic-peptide separation through dynamic electrostatic-repulsion reversed-phase (d-ERRP) liquid chromatography — RSC advances, 2020-03-27.
- Maroto A, Boqué R, Jeanne Dit Fouque D, Memboeuf A. Energy-Resolved Mass Spectrometry and Mid-Infrared Spectroscopy for Purity Assessment of a Synthetic Peptide Cyclised by Intramolecular Huisgen Click Chemistry — Methods and protocols, 2024-12-02.
- Streuli A, Erckes V, Nardone B, Bedard V, Beland F, Steuer C. Improvement of Analysis and Transferability in Peptide Purification: From HPLC to FPLC and Back Again — Journal of peptide science : an official publication of the European Peptide Society, 2026-03-01.
- Pohl T, Merkle PS, Hudelmaier S, Le-Minh V, Mertens D, Schmid C, Ossola R, Soenksen C, Zeiler M, Starikov A, Waterman E, Gutenbrunner P, DeGraan-Weber N, Englis. Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method — mAbs, 2025-10-13.
- Nicolás Carcelén J, Potes Rodríguez H, González-Gago A, Marchante-Gayón JM, Ballesteros A, González JM, García Alonso JI, Rodríguez-González P. Evaluation of different isotope dilution mass spectrometry strategies for the characterization of naturally abundant and isotopically labelled peptide standards — Analytical and bioanalytical chemistry, 2024-02-16.

